Freespira named one of Fast Company's 2023 Most Innovative Companies.

Freespira in Newsweek: Read Doug's patient story here.

Stephen Bruso_B&W

Stephen Bruso

Board Member

Stephen Bruso joined Morningside Ventures in 2019 and focuses on early-stage investments in the digital health space. He has extensive experience providing operational and management oversight to companies. Mr. Bruso serves as a director for numerous private companies including Cognito Therapeutics, Curai Health, Suvera, Neuroelectrics, Huckleberry, Ieso Digital Health, Wellinks, Curve Health, Koa Health, SimpliFed, and Blueberry Pediatrics; he is a board observer at Linus Health.

Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun out from the Church Lab at HMS before transitioning to the software space where he led the development and commercialization of e-commerce platforms for SMBs. He received his MBA from Boston University in 2019, graduating magna cum laude. He received his BA from Emory University in 2009.